15 October 2024
Argent BioPharma Ltd.
(Argent BioPharma or the Company)
PDMR Notification
Argent BioPharma Ltd (Argent BioPharma, RGT or the Company), advises of the following transaction which took place on 15 October 2024 whereby, Roby Zomer (Argent BioPharma's Managing Director & CEO) was issued 4,000,000 fully paid ordinary shares in Company at a price of A$0.41 each following the approval of resolution 1 at a general meeting of shareholders on 1 October 2024.
The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Roby Zomer | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Managing Director and Chief Executive Officer | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | Argent BioPharma Ltd
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
| (b) | Identification Code (ISIN)
| AU0000326647 | |||
| (c) | Nature of transaction | Shares issued in accordance with the passing of resolution 1 at a general meeting held 1 October 2024. | |||
| (d) | Currency | Price | Volume | Total | |
| | AUD | 0.41 | 4,000,000 | $1,640,000 | |
| | Aggregated information | ||||
| | AUD | 0.41 | 4,000,000 | $1,640,000 | |
| (e) | Date of transaction
| 15 October 2024 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
-Ends-
Authorised for release by the Company Secretary, for further information please contact:
| Argent BioPharma Limited Roby Zomer CEO & Managing Director +61 8 6555 2950
| Argent BioPharma Limited Rowan Harland Company Secretary +61 8 6555 2950
|
About Argent BioPharma
Argent BioPharma Limited (the Company) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector. The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the Central nervous system (CNS) and Immunology treatments.
Follow us through our social media channels:
LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
